ESMO: European Society for Medical Oncology

1. New Institutions Join AACR Project GENIE Consortium

   There are now four European institutions contributing to the registry

2. ESMO Emphasises Importance of Cancer on the Global Health Agenda at the 71st World Health Assembly [ESMO Press Release]

   At the 71st World Health Assembly (WHA) in Geneva, Switzerland, ESMO, the leading professional organisation for medical oncology, delivered two statements positioning cancer as a priority on the World Health Organisation’s (WHO) global agenda.

3. Phase III IMblaze370 Study Did Not Meet Its Primary Endpoint of Overall Survival

   Evaluation of the combination of atezolizumab and cobimetinib in heavily pre-treated locally advanced or metastatic CRC

4. No Evidence that FDA Breakthrough-Designated Anticancer Drugs Provide Improvements in Efficacy, Safety or Novelty

   Comparison with non–breakthrough-designated drugs reveals only faster times to approval

5. NICE Issues Technology Appraisal Guidance for Atezolizumab for Treating Locally Advanced or Metastatic NSCLC After Chemotherapy

   Atezolizumab is recommended if it is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses